A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow

Abstract

Summary: Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer. Cancer Discov; 4(9); 991–4. ©2014 AACR.

See related article by Janjigian et al., p. 1036